CS
SNDX icon

Candriam SCA’s Syndax Pharmaceuticals SNDX Stock Holding History

Candriam SCA’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.6M Hold
925,332
– – 0.11% 182
2025
Q4 		$19.4M Hold
925,332
– – 0.1% 191
2025
Q3 		$14.2M Buy
925,332
+250,247
+37% +$3.28M 0.07% 221
2025
Q2 		$6.32M Buy
675,085
+224,650
+50% +$2.47M 0.04% 315
2025
Q1 		$5.53M Sell
450,435
-96,730
-18% -$1.36M 0.03% 312
2024
Q4 		$7.23M Sell
547,165
-451,454
-45% -$7.73M 0.04% 304
2024
Q3 		$19.2M Buy
998,619
+28,513
+3% +$589K 0.11% 184
2024
Q2 		$19.9M Sell
970,106
-74,926
-7% -$1.57M 0.12% 169
2024
Q1 		$24.9M Buy
1,045,032
+24,000
+2% +$535K 0.16% 139
2023
Q4 		$22.1M Buy
1,021,032
+781,022
+325% +$12M 0.15% 151
2023
Q3 		$3.48M Hold
240,010
– – 0.02% 357
2023
Q2 		$5.02M Sell
240,010
-14,864
-6% -$309K 0.04% 331
2023
Q1 		$4.95M Buy
+254,874
New +$6.34M 0.03% 366
2021
Q2 		– Sell
-25,671
Closed -$548K – 936
2021
Q1 		$548K Hold
25,671
– – ﹤0.01% 704
2020
Q4 		$571K Sell
25,671
-332,701
-93% -$6.9M ﹤0.01% 717
2020
Q3 		$5.29M Buy
358,372
+10,914
+3% +$166K 0.05% 347
2020
Q2 		$5.15M Buy
+347,458
New +$5.29M 0.05% 325
2018
Q1 		– Sell
-70,000
Closed -$613K – 786
2017
Q4 		$613K Buy
+70,000
New +$693K 0.01% 647

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Candriam SCA's SNDX Position: Q1 2026 in Review

Candriam SCA held its Syndax Pharmaceuticals (SNDX) position steady in Q1 2026 at 925,332 shares worth $21.6M. The position accounts for 0.11% of the portfolio, ranked #182.

Candriam SCA first reported a position in SNDX in Q4 2017 and has held it in 18 quarters since. The position peaked at $24.9M in Q1 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Candriam SCA held 925,332 shares of Syndax Pharmaceuticals worth $21.6M as of Q1 2026.
  • Candriam SCA left its Syndax Pharmaceuticals share count unchanged in Q1 2026.
  • Syndax Pharmaceuticals made up 0.11% of Candriam SCA's portfolio in Q1 2026, its #182 holding.
  • Candriam SCA first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 18 quarters since.
  • Candriam SCA's Syndax Pharmaceuticals position peaked at $24.9M in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.